NCT05464992 Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI
| NCT ID | NCT05464992 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Paul Strauss |
| Condition | Glioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2022-12-28 |
| Primary Completion | 2036-12-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2022-12-28 with a primary completion date of 2036-12-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Standard Magnetic Resonance Imaging (MRI) is based on the excitation of hydrogen nuclei that are presents in water molecules, which abundance in human body allows for obtention of superior contrast. However, assessing the presence of other molecules than water in tissues is also of great clinical interest to probe metabolites related to physiological body function and pathological conditions. Chemical exchange saturation transfer (CEST) allow to overcome some limitations of proton magnetic resonance spectroscopy (1H-MRS) by exploiting chemical properties of the targeted molecule through a continuous process of re-saturation and exchange, and thus detecting it with increased sensitivity, from two orders of magnitude. Moreover, CEST technique is based on imaging sequences and can therefore benefit from well-known fast acquisition strategies, as well as improved spatial resolution.
Eligibility Criteria
Inclusion Criteria: Patients admitted to the Nuclear Medicine and Molecular Imaging department of ICANS (Institut de cancérologie strasbourg Europe) for a PET/MRI exam dedicated to: * Preoperative evaluation of a cerebral expansion lesion * Evaluation of glioma recurrences * Evaluation of brain metastases * Evaluation of recurrence of metastases Exclusion Criteria: * Contraindication to the realization of an MRI * Minor or patients placed under guardianship or supervision * Patients deprived of liberty * Patients placed under judicial protection * Patients that are not able to express their consent * Pregnant and breastfeeding women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05464992 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05464992 currently recruiting?
Yes, NCT05464992 is actively recruiting participants. Contact the research team at promotion-rc@icans.eu for enrollment information.
Where is the NCT05464992 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT05464992 clinical trial?
NCT05464992 is sponsored by Centre Paul Strauss. The trial plans to enroll 800 participants.